<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498055</url>
  </required_header>
  <id_info>
    <org_study_id>GLiang</org_study_id>
    <nct_id>NCT01498055</nct_id>
  </id_info>
  <brief_title>Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study</brief_title>
  <acronym>CIK</acronym>
  <official_title>A Randomized Controlled Trail on the Efficacy and Safety of Autologous Cytokine-induced Killer (CIK) Cells Infusion Treatment in Advanced Primary Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trail on the efficacy and safety of autologous cytokine-induced&#xD;
      killer (CIK) cells infusion treatment in advanced primary lung cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rates (DCR)</measure>
    <time_frame>From 12-2011 to 12-2013</time_frame>
    <description>Lung lesions of disease control rates DCR (CR + PR + SD), according to solid tumor response evaluation standard (response evaluation criteria in solid tumors, RECIST) standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Disease progression-free surial (Progression-Free Srvival, PFS) with observations</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CIK therapy group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The one-time folic acid sodium anticoagulation vacuum picks bag, through the venous blood&#xD;
      sampling 60 ml. When blood alcohol on parts of the need blood disinfects processing. After&#xD;
      the department shows will seal in a sterile bag, 16-21 degrees Celsius save, and transported&#xD;
      to a cell biological treatment as soon as possible a follow-up operation center GMP&#xD;
      laboratory.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary lung cancer diagnosis (including small cell lung cancer, lung adenocarcinoma, lung&#xD;
        squamous cell carcinoma and large cell carcinoma) patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18~70 year old, KPS score &gt;50 points, estimate survival &gt; 3 months;&#xD;
&#xD;
          -  Primary lung cancer patients after chemotherapy or radiation therapy;&#xD;
&#xD;
          -  Primary lung cancer patients after targeted therapy;&#xD;
&#xD;
          -  Primary lung cancer patients with lung function can not accept operation or unwilling&#xD;
             to operation;&#xD;
&#xD;
          -  Primary lung cancer recurrence or surgery can't complete resection;&#xD;
&#xD;
          -  Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf,&#xD;
             etc.);&#xD;
&#xD;
          -  No serious mental illness and no serious heart, liver, kidney diseases, unincorporated&#xD;
             other potentially lethal diseases;&#xD;
&#xD;
          -  Patients Voluntary attempt, and informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiovascular disease: congestive heart failure &gt; New York heart&#xD;
             association (NYHA) level II, unstable angina patients (resting when the angina&#xD;
             symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of&#xD;
             myocardial infarction;&#xD;
&#xD;
          -  Cachexia; or other deadly diseases;&#xD;
&#xD;
          -  Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney&#xD;
             TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;&#xD;
&#xD;
          -  Active infection;&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  At present Is receiving other cancer treatment (such as chemotherapy, radiation&#xD;
             therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);&#xD;
&#xD;
          -  Now or recently will join another experimental clinical study ;&#xD;
&#xD;
          -  Other situations that the researchers considered unsuitable for this study (such as&#xD;
             mental illness, drug abuse, HIV infections, etc.), or influence on the results of&#xD;
             clinical trials for analysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangdong Zhou</last_name>
    <role>Study Chair</role>
    <affiliation>Southwest Hospital Third Military University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liang Gong</name>
      <address>
        <city>Chong Qing</city>
        <state>Chong Qing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Gong</last_name>
      <phone>13983965893</phone>
      <email>gonglw1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Liang Gong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>November 24, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Gong Liang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>CIK cells</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

